Skip to Content
Merck

Precise druggability of the PTH type 1 receptor.

Nature chemical biology (2021-12-25)
Ieva Sutkeviciute, Ji Young Lee, Alex D White, Christian Santa Maria, Karina A Peña, Sofya Savransky, Pemra Doruker, Hongchun Li, Saifei Lei, Burak Kaynak, Chialing Tu, Lisa J Clark, Subramaniam Sanker, Thomas J Gardella, Wenhan Chang, Ivet Bahar, Jean-Pierre Vilardaga
ABSTRACT

Class B G protein-coupled receptors (GPCRs) are notoriously difficult to target by small molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain limits the identification and development of nonpeptide small molecule ligands. Using the parathyroid hormone type 1 receptor (PTHR) as a prototypic class B GPCR target, and a combination of molecular dynamics simulations and elastic network model-based methods, we demonstrate that PTHR druggability can be effectively addressed. Here we found a key mechanical site that modulates the collective dynamics of the receptor and used this ensemble of PTHR conformers to identify selective small molecules with strong negative allosteric and biased properties for PTHR signaling in cell and PTH actions in vivo. This study provides a computational pipeline to detect precise druggable sites and identify allosteric modulators of PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic candidates.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution